OncoCyte EBITDA 2014-2024 | OCX
OncoCyte ebitda from 2014 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
| OncoCyte Annual EBITDA (Millions of US $) |
|
|---|---|
| 2023 | $-23 |
| 2022 | $6 |
| 2021 | $-49 |
| 2020 | $-29 |
| 2019 | $-22 |
| 2018 | $-14 |
| 2017 | $-18 |
| 2016 | $-11 |
| 2015 | $-8 |
| 2014 | $-5 |
| 2013 | $-3 |
| OncoCyte Quarterly EBITDA (Millions of US $) |
|
|---|---|
| 2024-09-30 | $-13 |
| 2024-06-30 | $-4 |
| 2024-03-31 | $-9 |
| 2023-12-31 | $-16 |
| 2023-09-30 | $-6 |
| 2023-06-30 | $-8 |
| 2023-03-31 | $6 |
| 2022-12-31 | $8 |
| 2022-09-30 | $-0 |
| 2022-06-30 | $-0 |
| 2022-03-31 | $-2 |
| 2021-12-31 | $-14 |
| 2021-09-30 | $-12 |
| 2021-06-30 | $-12 |
| 2021-03-31 | $-11 |
| 2020-12-31 | $-7 |
| 2020-09-30 | $-5 |
| 2020-06-30 | $-9 |
| 2020-03-31 | $-8 |
| 2019-12-31 | $-7 |
| 2019-09-30 | $-5 |
| 2019-06-30 | $-5 |
| 2019-03-31 | $-4 |
| 2018-12-31 | $-4 |
| 2018-09-30 | $-3 |
| 2018-06-30 | $-3 |
| 2018-03-31 | $-4 |
| 2017-12-31 | $-4 |
| 2017-09-30 | $-7 |
| 2017-06-30 | $-3 |
| 2017-03-31 | $-4 |
| 2016-12-31 | $-3 |
| 2016-09-30 | $-2 |
| 2016-06-30 | $-2 |
| 2016-03-31 | $-3 |
| 2015-12-31 | $-3 |
| 2015-09-30 | $-2 |
| 2015-06-30 | $-1 |
| 2015-03-31 | $-1 |
| 2014-12-31 | |
| 2013-12-31 | |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $0.035B | $0.002B |
| OncoCyte Corporation is primarily focused on the development of novel, non-invasive blood and urine diagnostic tests for detection of cancer. OncoCyte Corporation is based in Alameda, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Elevance Health (ELV) | United States | $89.358B | 11.09 |
| Cencora (COR) | United States | $46.783B | 17.59 |
| DiDi Global (DIDIY) | China | $22.844B | 0.00 |
| Natera (NTRA) | United States | $20.907B | 0.00 |
| ICON (ICLR) | Ireland | $16.343B | 14.56 |
| Avantor (AVTR) | United States | $15.048B | 22.56 |
| Revvity (RVTY) | United States | $14.408B | 25.03 |
| BioMerieux (BMXMF) | France | $13.788B | 0.00 |
| Viatris (VTRS) | United States | $13.488B | 4.15 |
| Solventum (SOLV) | United States | $12.699B | 0.00 |
| CochLear (CHEOY) | Australia | $12.341B | 0.00 |
| Medpace Holdings (MEDP) | United States | $10.485B | 29.54 |
| Doximity (DOCS) | United States | $10.029B | 59.03 |
| EUROFINS SCIENT (ERFSF) | Luxembourg | $9.551B | 0.00 |
| HealthEquity (HQY) | United States | $8.876B | 44.53 |
| Charles River Laboratories (CRL) | United States | $8.361B | 16.16 |
| Sonic Healthcare (SKHHY) | Australia | $8.244B | 0.00 |
| Amplifon S.p.A (AMFPF) | Italy | $6.136B | 31.28 |
| Bausch + Lomb (BLCO) | Canada | $6.118B | 28.46 |
| Organon (OGN) | United States | $4.054B | 4.09 |
| Sotera Health (SHC) | United States | $3.676B | 19.67 |
| BrightSpring Health Services (BTSG) | United States | $3.230B | 68.70 |
| Alignment Healthcare (ALHC) | United States | $2.795B | 0.00 |
| Concentras Parent (CON) | United States | $2.691B | 0.00 |
| Surgery Partners (SGRY) | United States | $2.566B | 29.26 |
| Premier (PINC) | United States | $2.156B | 11.22 |
| PACS (PACS) | United States | $2.106B | 0.00 |
| Ardent Health Partners (ARDT) | United States | $2.013B | 0.00 |
| GeneDx Holdings (WGS) | United States | $1.909B | 0.00 |
| Progyny (PGNY) | United States | $1.788B | 36.21 |
| GoodRx Holdings (GDRX) | United States | $1.742B | 45.70 |
| Ryman Healthcare (RYHTY) | New Zealand | $1.658B | 0.00 |
| Teladoc Health (TDOC) | United States | $1.565B | 0.00 |
| Agilon Health (AGL) | United States | $1.273B | 0.00 |
| Pediatrix Medical (MD) | United States | $1.189B | 11.63 |
| CareDx (CDNA) | United States | $1.150B | 0.00 |
| Embecta (EMBC) | United States | $1.086B | 7.59 |
| AMN Healthcare Services Inc (AMN) | United States | $0.986B | 6.67 |
| Establishment Labs Holdings (ESTA) | $0.968B | 0.00 | |
| Auna S.A (AUNA) | Luxembourg | $0.624B | 0.00 |
| SBC Medicals (SBC) | United States | $0.518B | 0.00 |
| InnovAge Holding (INNV) | United States | $0.484B | 0.00 |
| Sonida Senior Living (SNDA) | United States | $0.429B | 0.00 |
| QDM (QDMI) | Hong Kong, SAR China | $0.426B | 11.15 |
| DocGo (DCGO) | United States | $0.426B | 16.04 |
| Enhabit (EHAB) | United States | $0.402B | 34.74 |
| MultiPlan (MPLN) | United States | $0.260B | 0.00 |
| COMPASS Pathways (CMPS) | United Kingdom | $0.239B | 0.00 |
| Sera Prognostics (SERA) | United States | $0.217B | 0.00 |
| Beauty Health (SKIN) | United States | $0.216B | 0.00 |
| LifeMD (LFMD) | United States | $0.212B | 0.00 |
| Nutex Health (NUTX) | United States | $0.206B | 0.00 |
| Performant Healthcare (PHLT) | United States | $0.181B | 0.00 |
| Biodesix (BDSX) | United States | $0.167B | 0.00 |
| So-Young (SY) | China | $0.110B | 18.60 |
| ModivCare (MODV) | United States | $0.093B | 5.03 |
| Ascend Wellness Holdings (AAWH) | United States | $0.085B | 0.00 |
| IceCure Medical (ICCM) | Israel | $0.068B | 0.00 |
| NeueHealth (NEUE) | United States | $0.062B | 1.63 |
| Singular Genomics Systems (OMIC) | United States | $0.050B | 0.00 |
| Oncology Institute (TOI) | United States | $0.042B | 0.00 |
| NeuroOne Medical Technologies (NMTC) | United States | $0.032B | 0.00 |
| Co-Diagnostics (CODX) | United States | $0.025B | 0.00 |
| Pheton Holdings (PTHL) | China | $0.025B | 0.00 |
| KindlyMD (KDLY) | United States | $0.009B | 0.00 |
| SeaStar Medical Holding (ICU) | United States | $0.008B | 0.00 |
| BioNexus Gene Lab (BGLC) | $0.007B | 0.00 | |
| XWELL (XWEL) | United States | $0.007B | 0.00 |
| Intelligent Bio Solutions (INBS) | United States | $0.006B | 0.00 |
| NewGenIvf Group (NIVF) | Thailand | $0.004B | 0.00 |
| ISpecimen (ISPC) | United States | $0.002B | 0.00 |
| Aclarion (ACON) | United States | $0.001B | 0.00 |
| Cano Health (CANOQ) | United States | $0.000B | 0.00 |